Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
<p>SNP ID.</p>
Sparad:
| Huvudupphovsman: | Francesca Orzan (15055579) (author) |
|---|---|
| Övriga upphovsmän: | Francesca De Bacco (15055582) (author), Elisabetta Lazzarini (15055585) (author), Giovanni Crisafulli (15055588) (author), Alessandra Gasparini (15019568) (author), Angelo Dipasquale (15055591) (author), Ludovic Barault (15030747) (author), Marco Macagno (15030744) (author), Pasquale Persico (15055594) (author), Federico Pessina (15055597) (author), Beatrice Bono (15055600) (author), Laura Giordano (15055603) (author), Pietro Zeppa (15055606) (author), Antonio Melcarne (15055609) (author), Paola Cassoni (15055612) (author), Diego Garbossa (15055615) (author), Armando Santoro (15034235) (author), Paolo M. Comoglio (15055618) (author), Stefano Indraccolo (15027102) (author), Matteo Simonelli (15055621) (author), Carla Boccaccio (15055624) (author) |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Liknande verk
Liknande verk
-
Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
av: Francesca Orzan (15055579)
Publicerad: (2025) -
Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
av: Francesca Orzan (15055579)
Publicerad: (2025) -
Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
av: Michael Kilian (16697663)
Publicerad: (2025) -
Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
av: Michael Kilian (16697663)
Publicerad: (2025) -
Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
av: Michael Kilian (16697663)
Publicerad: (2025)